Helix BioPharma Narrows Losses Amid Strategic Shift to Lung Cancer Focus
Helix BioPharma reported reduced financial losses for fiscal 2025 while implementing a strategic pivot to focus exclusively on developing its L-DOS47 treatment for non-small cell lung cancer in combination with immunotherapy.
Helix BioPharma Corp. reported a net loss of $5.2 million for the fiscal year ended July 31, 2025, representing a significant improvement from the $9.3 million loss recorded in the previous year. The clinical-stage oncology company also reduced its loss per common share to $0.09 from $0.21 in fiscal 2024, reflecting progress in controlling expenses while advancing its pipeline.
The company's strategic transformation included a comprehensive review of assets that resulted in focusing resources exclusively on developing L-DOS47 as a combination therapy with pembrolizumab for first-line treatment of non-small cell lung carcinoma. This decision was driven by expert analysis of clinical data, the significant unmet medical need in NSCLC despite immunotherapy advances, and assessment of where tumor alkalization therapy could deliver near-term clinical impact with the shortest path to FDA approval.
As part of this strategic shift, Helix terminated research collaborations with University of Tuebingen in Germany and Peter Mac in Australia on August 9 and 13, 2024, respectively, as these projects fell outside the new NSCLC focus. The company also closed its Edmonton laboratory on October 31, 2024, liquidating equipment and transferring materials to third-party storage. Manufacturing optimization discussions with contract drug manufacturing organizations were initiated to prepare for future drug production.
The company completed its Phase Ib/II combination trial in metastatic pancreatic adenocarcinoma in October 2024, with data analysis ongoing and a clinical study report expected in fall 2025. Meanwhile, planning advanced for LDOS007, a new Phase Ib/Randomized Phase II study evaluating L-DOS47 with pembrolizumab in NSCLC. The U.S. Food and Drug Administration provided positive written feedback on the study design on August 8, 2025, enabling the company to proceed directly with clinical trial application preparation.
Research and development expenses decreased by 40% to $3.6 million, while operating, general and administration expenses dropped 43% to $1.8 million. These reductions resulted from concluded clinical trials, changes in service providers, and streamlined operations following the strategic refocus.
Corporate developments included significant leadership changes, with Thomas Mehrling, MD, PhD appointed CEO on April 10, 2025, and Rohit Babbar named CFO on June 2, 2025. The company strengthened its financial position through private placements, raising $3 million on January 8, 2025, and $1.7 million on August 22, 2025. However, the company reported a working capital deficiency of $2.8 million and cash reserves of only $65,000 as of July 31, 2025, insufficient to meet anticipated needs over the next twelve months.
The company's financial statements and related documents are available on SEDAR+ at https://www.sedarplus.ca/ and through the company website at https://www.helixbiopharma.com/. The strategic pivot to NSCLC represents a calculated bet on L-DOS47's potential to address persistent challenges in lung cancer treatment, where immunotherapy alone often proves insufficient for many patients.